HeartBeam Inc. (NASDAQ: BEAT) announced it will attend the JP Morgan 2026 Annual Healthcare Conference from January 12 to 15, 2026, in San Francisco, where company executives will meet with investors and potential partners to discuss its recently FDA-cleared cardiac technology. The company's Chief Executive Officer Robert Eno and Chief Financial Officer Timothy Cruickshank will be available for off-site meetings from January 12 to 14 at the Westin St. Francis Hotel.
The discussions are expected to focus on HeartBeam's 510(k) clearance from the U.S. Food and Drug Administration for its patented, cable-free 12-lead electrocardiogram synthesis software for arrhythmia assessment. This clearance positions the company for a planned limited U.S. commercial launch in the first quarter of 2026. The technology represents a significant advancement in cardiac care by enabling portable, remote monitoring outside traditional medical facilities.
HeartBeam's platform technology creates the first cable-free device capable of collecting ECG signals in three dimensions from three non-coplanar directions and synthesizing these signals into a 12-lead ECG. This innovation allows physicians to identify cardiac health trends and acute conditions while patients are outside medical facilities, potentially transforming how cardiac conditions are detected and monitored. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, followed by clearance for the 12-Lead ECG synthesis software in December 2025.
The HeartBeam System is a portable non-invasive recorder intended to record, store, and transfer a patient's 3-lead ECG acquired from five electrodes. According to the cleared indications for use available at https://nnw.fm/zvmUc, the device is intended for adult patients in clinical or home settings and does not conduct cardiac analysis itself. The synthesized 12-lead ECG output is solely intended for manual assessment of normal sinus rhythm and specific non-life-threatening arrhythmias, including sinus arrhythmia, sinus tachycardia, sinus bradycardia, atrial premature complexes, atrial fibrillation, and ventricular premature complex.
Importantly, the synthesized output is not intended for assessment of other conditions such as ventricular arrhythmias, hypertrophy, conduction disorders, myocardial infarction or ischemia, pacemaker functions, or localization of arrhythmia foci. The software does not conduct cardiac analysis and is not intended to replace a standard 12-lead ECG. HeartBeam holds over 20 issued patents related to its technology enablement, demonstrating the proprietary nature of its innovation.
The company's participation in the prestigious JP Morgan healthcare conference signals its readiness to engage with the investment and medical communities as it prepares for commercialization. This development matters because it represents progress toward making sophisticated cardiac monitoring more accessible outside hospital settings, potentially enabling earlier detection of cardiac issues and reducing healthcare burdens. The technology's ability to provide actionable heart intelligence wherever the patient is could significantly impact how cardiac conditions are managed, particularly for patients requiring ongoing monitoring but not immediate hospitalization.
